AbbVie says real — world studies show Vraylar improves symptoms in MDD, bipolar I depression
AbbVie presented new real-world study findings on VRAYLAR at Psych Congress 2026 in New Orleans. In observational studies in bipolar I depression and adjunctive major depressive disorder, patients showed meaningful improvement in symptoms and daily functioning. Reported tolerability was consistent with established use,